Table 2.
Types of Neonatal Antiretroviral Prophylaxis Received By 6386 Newborns in the First 8 Weeks of Life
| Type of neonatal ARV prophylaxis | ARV prophylaxis regimen | N (%) |
|---|---|---|
| No ARV prophylaxis | 568 (8.9) | |
| Monotherapy | 5200 (81.4) | |
| Zidovudine alone | ZDV | 5170 (81.0) |
| Other monotherapy (n = 30) | Stavudine (d4T) | 18 (0.3) |
| Nevirapine (NVP) | 9 (0.1) | |
| Lamivudine (3TC) | 2 (<0.1) | |
| Ritonavir (RTV) | 1 (<0.1) | |
| ZDV+single-dose NVP | ZDV+SD NVP | 253 (4.0) |
| Combination ARV prophylaxisa | 365 (5.7) | |
| Ever on 2-drug regimen | 317 (5.0) | |
| Ever on 3-drug or 4-drug regimen | 133 (2.1) |
| Specific regimens for combination prophylaxis | N (% among category) | |
|---|---|---|
| 2-drug regimens | ZDV +3TC | 219 (66.8) |
| (328 regimens received by 317 unique newborns) | ZDV+NVP | 85 (25.9) |
| 3TC+nelfinavir (NFV) | 4 (1.2) | |
| ZDV+abacavir (ABC) | 3 (0.9) | |
| ZDV+didanosine (ddI) | 3 (0.9) | |
| ZDV+d4T | 2 (0.6) | |
| ZDV+NFV | 2 (0.6) | |
| 3TC+d4T | 2 (0.6) | |
| Other 2-drug regimens | 8 (2.4) | |
| 3-drug or 4-drug regimens | ZDV+3TC+NVP | 94 (65.3) |
| (144 regimens received by 133 unique newborns) | ZDV+3TC+NFV | 18 (12.5) |
| ZDV+3TC+d4T | 7 (4.8) | |
| ZDV+3TC+lopinavir/ritonavir (LPV/r) | 4 (2.8) | |
| ZDV+emtricitabine (FTC)+tenofovir disoproxil fumarate (TDF) | 4 (2.8) | |
| 3TC+d4T+NVP | 2 (1.4) | |
| Other 3-drug regimens | 5 (3.5) | |
| ZDV+3TC+NVP+NFV | 3 (2.1) | |
| ZDV+3TC+NVP+LPV/r | 2 (1.4) | |
| ZDV+3TC+NVP+raltegravir (RAL) | 2 (1.4) | |
| Other 4-drug regimens | 3 (2.1) |
a
Note that infants may have received multiple neonatal prophylaxis regimens during the first 8 weeks and thus percentages may not add to 100%.
3TC, lamivudine; d4T, stavudine; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; SD NVP, single-dose nevirapine; ZDV, zidovudine.